Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-05-31T02:10:02Z | - |
dc.date.available | 2018-05-31T02:10:02Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.citation | COLLOIDS AND SURFACES B-BIOINTERFACES, v. 150, Page. 393-401 | en_US |
dc.identifier.issn | 0927-7765 | - |
dc.identifier.issn | 1873-4367 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0927776516307780 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/71740 | - |
dc.description.abstract | In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of PEGylated polypeptide-lipid nanocapsules (PLN) for erlotinib (ERL) delivery was similar to 200 nm with an effective surface charge of -20 mV. Protective PEGylated polypeptide layer acted as a molecular fence and effectively controlled the diffusion of erlotinib from the lipid nanocapsule core, whereas pH-responsiveness of poly(L-aspartic acid) accelerated the release of erlotinib in acidic conditions. Blank lipid nanocapsules showed excellent bio-compatibility. ERL-loaded PLN (ERL-PLN) showed dose-dependent cytotoxicity in NCl-H358 and HCC-827 lung cancer cells. ERL-PLN treatment resulted in a superior tumor regression profile in a xenograft tumor model, compared to free ERL and control, suggesting high therapeutic efficacy. ERL-PLN-treated mice showed 5- and 2-fold smaller tumor volume compared to control and free ERL groups, respectively. Based on these results, PLN provide a promising drug delivery approach for lung cancer therapy. (C) 2016 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01004118, 2015R1A2A2A04004806). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Erlotinib | en_US |
dc.subject | Polypeptide | en_US |
dc.subject | Nanocapsules | en_US |
dc.subject | Antitumor efficacy | en_US |
dc.subject | Lung cancer | en_US |
dc.subject | POLYELECTROLYTE COMPLEX MICELLES | en_US |
dc.subject | POLYMER HYBRID NANOPARTICLES | en_US |
dc.subject | DRUG-DELIVERY | en_US |
dc.subject | IN-VITRO | en_US |
dc.subject | ANTITUMOR EFFICACY | en_US |
dc.subject | CHEMOTHERAPY | en_US |
dc.subject | IRINOTECAN | en_US |
dc.subject | INHIBITORS | en_US |
dc.subject | PLATFORM | en_US |
dc.title | PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer | en_US |
dc.type | Article | en_US |
dc.relation.volume | 150 | - |
dc.identifier.doi | 10.1016/j.colsurfb.2016.11.002 | - |
dc.relation.page | 393-401 | - |
dc.relation.journal | COLLOIDS AND SURFACES B-BIOINTERFACES | - |
dc.contributor.googleauthor | Kim, Jeonghwan | - |
dc.contributor.googleauthor | Ramasamy, Thiruganesh | - |
dc.contributor.googleauthor | Choi, Ju Yeon | - |
dc.contributor.googleauthor | Kim, Ssang Tae | - |
dc.contributor.googleauthor | Youn, Yu Seok | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Yong, Chul Soon | - |
dc.contributor.googleauthor | Kim, Jong Oh | - |
dc.relation.code | 2017001472 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.